738 related articles for article (PubMed ID: 34823553)
21. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
22. Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.
Valero C; Golkaram M; Vos JL; Xu B; Fitzgerald C; Lee M; Kaplan S; Han CY; Pei X; Sarkar R; Boe LA; Pandey A; Koh ES; Zuur CL; Solit DB; Pawlowski T; Liu L; Ho AL; Chowell D; Riaz N; Chan TA; Morris LG
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561583
[TBL] [Abstract][Full Text] [Related]
23. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
Wang Z; Goto Y; Allevato MM; Wu VH; Saddawi-Konefka R; Gilardi M; Alvarado D; Yung BS; O'Farrell A; Molinolo AA; Duvvuri U; Grandis JR; Califano JA; Cohen EEW; Gutkind JS
Nat Commun; 2021 Apr; 12(1):2383. PubMed ID: 33888713
[TBL] [Abstract][Full Text] [Related]
24. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
[TBL] [Abstract][Full Text] [Related]
25. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma.
Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J
BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580
[TBL] [Abstract][Full Text] [Related]
26. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
[TBL] [Abstract][Full Text] [Related]
27. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in head and neck squamous cell carcinoma.
He F; Chen Z; Deng W; Zhan T; Huang X; Zheng Y; Yang H
Int Immunopharmacol; 2021 Sep; 98():107789. PubMed ID: 34130150
[TBL] [Abstract][Full Text] [Related]
29. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
30. Tumor-Infiltrating Immune-Related Long Non-Coding RNAs Indicate Prognoses and Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma.
Ma B; Jiang H; Luo Y; Liao T; Xu W; Wang X; Dong C; Ji Q; Wang Y
Front Immunol; 2021; 12():692079. PubMed ID: 34737735
[TBL] [Abstract][Full Text] [Related]
31. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
[TBL] [Abstract][Full Text] [Related]
32. Identification of Immune-Related Prognostic Biomarkers Associated with HPV-Positive Head and Neck Squamous Cell Carcinoma.
Chen Y; Nie J; Li X; Fan T; Deng X; Liang D; Song G
J Immunol Res; 2021; 2021():6661625. PubMed ID: 33506058
[TBL] [Abstract][Full Text] [Related]
33. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
34. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
Chen SW; Li SH; Shi DB; Jiang WM; Song M; Yang AK; Li YD; Bei JX; Chen WK; Zhang Q
Int J Biol Markers; 2019 Dec; 34(4):398-405. PubMed ID: 31674884
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
36. Immune-related miRNA signature identifies prognosis and immune landscape in head and neck squamous cell carcinomas.
Ma B; Li H; Qiao J; Meng T; Yu R
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33111959
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
Cristina V; Herrera-Gómez RG; Szturz P; Espeli V; Siano M
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671550
[TBL] [Abstract][Full Text] [Related]
38. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
39. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
Gavrielatou N; Fortis E; Spathis A; Anastasiou M; Economopoulou P; Foukas GRP; Lelegiannis IM; Rusakiewicz S; Vathiotis I; Aung TN; Tissot S; Kastrinou A; Kotsantis I; Vagia EM; Panayiotides I; Rimm DL; Coukos G; Homicsko K; Foukas P; Psyrri A
Ann Oncol; 2024 Apr; 35(4):340-350. PubMed ID: 38159908
[TBL] [Abstract][Full Text] [Related]
40. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX
Front Immunol; 2021; 12():791621. PubMed ID: 35003112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
